NEWARK, Del.--(BUSINESS WIRE)--iBio, Inc. (OTCBB: IBPM) announced today that the U.S. Food and Drug Administration (FDA) accepted another Investigational New Drug (IND) application filed for a product candidate made with the Company’s proprietary, transformative technology, the iBioLaunch™ technology platform.
